



AACR Special Conference in Cancer Research

INNOVATIONS IN PROSTATE CANCER RESEARCH AND TREATMENT

Jan. 20-22 | Boston, MA

AACR

American Association
for Cancer Research®

2507016H

Lightning Talks I

6:30-7:30 p.m. | Essex Ballroom

Session Chair: Eliezer Van Allen, DFCI

1. **Docetaxel and the Tumor Targeting Interleukin-12 (IL-12) PDS01ADC in Patients with Metastatic Castration Resistant Prostate Cancer (mCRPC)***
Melissa Lauren Abel
National Institute of Health, Bethesda, MD
2. **A dependency map of androgen receptor activity identifies drivers of prostate cancer growth***
Arnab Bose
Fred Hutchinson Cancer Center, Seattle, WA
3. **High-dimensional spatial profiling identifies distinct and targetable tumor-infiltrating lymphocyte phenotypes in localized prostate cancer***
Precious Cramer
Beth Israel Deaconess Medical Center, Boston, MA
4. **Spatial Mapping of Accessible Chromatin Landscapes in Prostate Cancer***
Leigh Ellis
Center for Prostate Disease Research, Bethesda, MD
5. **Divergent FOXA1 mutations drive prostate tumorigenesis and therapy-resistant cellular plasticity***
Sanjana Eyunni
University of Michigan, Ann Arbor, MI
6. **Comprehensive spatial profiling of prostate cancer metastasis: Mapping clonal evolution, microenvironment dynamics, and early metastatic markers***
Mengxiao He
Science for Life Laboratory, Solna, Sweden
7. **PARP Inhibition Beyond BRCA in Prostate Cancer: The Roles of MMS22L and NDUFAF4***
Li Jia
Brigham and Women's Hospital/Harvard Medical School, Boston, MA
8. **Super-enhancer landscape analysis reveals a HOXB13-HNF1A transcriptional axis driving hepatic reprogramming in castration-resistant prostate cancer***
Mingyu Liu
University of Massachusetts, Boston, MA
9. **The temporal dynamics of the immune response to neoadjuvant androgen deprivation therapy suggest a window-of-opportunity for checkpoint inhibitor therapy in prostate cancer***



AACR Special Conference in Cancer Research

INNOVATIONS IN PROSTATE CANCER RESEARCH AND TREATMENT

Jan. 20-22 | Boston, MA

AACR

American Association
for Cancer Research®

2507016H

Kent Nastiuk

Roswell Park, Buffalo, NY

10. **Dissecting the role of CHD1 as a key regulator of pro-metastatic transcriptional reprogramming in BRCA2-mutant prostate cancer**

Jingzhu Hao

University of Massachusetts, Boston, MA

11. **Enhancing androgen receptor antagonist-mediated interferon responses in prostate cancer***

Larysa Polubien

Beth Israel Deaconess Medical Center, Boston, MA

12. **Combining CBP/p300 and PARP inhibitors to enhance anti-tumor efficacy in lethal prostate cancer***

Orly I. Richter

National Cancer Institute, Bethesda, MD

13. **Targeting of FOXA1 and FOXA2 by small molecules disables the oncogenic output of castration resistant prostate cancer***

Jean-Philippe Paul Theurillat

Institute of Oncology Research, Bellinzona, Switzerland

14. **A cancer vaccine for de novo metastatic prostate cancer: learning patients stratification from the UV1 trial***

Alfonso Urbanucci

Oslo University Hospital, Oslo, Norway

15. **Polycomb dysregulation shapes chromatin bivalency critical for prostate cancer lineage plasticity***

Varadha Balaji Venkadakrishnan

Dana-Farber Cancer Institute, Boston, MA

16. **Development of a fully humanized vascularized "tumor on a chip" model for prostate cancer liver metastasis***

Katherine Vietor

University of Wisconsin-Madison, Madison, WI

17. **Circulating tumor DNA methylation captures epigenetic changes in patients induced by the PRC2 inhibitor ORIC-944***

Amber W. Wang

ORIC Pharmaceuticals, South San Francisco, CA

18. **A bypass gateway from cholesterol to sex steroid biosynthesis circumnavigates CYP17A1***

Ziqi Zhu

University of Miami, FL